Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Serina Therapeutics, Inc. (SER) had Stock-Based Compensation of $1.08M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-6.90M |
|
-- |
|
-- |
|
$6.28M |
|
$-6.28M |
|
$-0.61M |
|
$-6.89M |
|
$-6.89M |
|
$-6.90M |
|
$-6.90M |
|
$-6.90M |
|
$-6.90M |
|
$-6.28M |
|
$-6.20M |
|
12.05M |
|
12.05M |
|
$-0.58 |
|
$-0.58 |
|
| Balance Sheet Financials | |
$26.47M |
|
$0.47M |
|
$0.82M |
|
$27.30M |
|
$6.34M |
|
$3.01M |
|
$3.33M |
|
$9.67M |
|
$12.69M |
|
$17.63M |
|
$17.63M |
|
14.90M |
|
| Cash Flow Statement Financials | |
$-4.57M |
|
$-0.03M |
|
$26.06M |
|
$3.06M |
|
$24.53M |
|
$21.47M |
|
|
Stock-Based Compensation |
$1.08M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.18 |
|
-- |
|
-- |
|
0.15 |
|
0.17 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.37% |
|
-39.13% |
|
-25.27% |
|
-33.42% |
|
$1.18 |
|
$-0.38 |
|
$-0.38 |
|